IDH2 and central nervous system cancer: Testing IDH wild type gliomas if bearing EGFR amplification, TERT promoter region mutation, or chromosome 7 gain and chromosome 10 loss genetic alterations versus other gliomas, could be similarly used to classify glioblastoma (WHO classification 5th edition 2021) [12, 42] samples.